{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zou F"],"funding":["NCI NIH HHS","National Institutes of Health"],"pagination":["e003277"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8601082"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(11)"],"pubmed_abstract":["<h4>Background</h4>Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC) recommend steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) for refractory cases. We aimed to compare the efficacy of these two SITs and their impact on cancer outcomes.<h4>Methods</h4>We performed a two-center, retrospective observational cohort study of patients with IMDC who received SITs following steroids from 2016 to 2020. Patients' demographic, clinical, and overall survival data were collected and analyzed.<h4>Results</h4>A total of 184 patients (62 vedolizumab, 94 infliximab, 28 combined sequentially) were included. The efficacy of achieving clinical remission of IMDC was similar (89% vs 88%, p=0.79) between the two groups."],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study."],"pmcid":["PMC8601082"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Sharon E","Richards DM","Thomas A","Ernstoff MS","Thompson J","Hanauer S","Zou F","Satish D","Glitza Oliva IC","Shah A","Faleck D","Charabaty A","Wang X","Harris J","Wang Y","McQuade J","Obeid M","Wolchok J"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.","description":"<h4>Background</h4>Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC) recommend steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) for refractory cases. We aimed to compare the efficacy of these two SITs and their impact on cancer outcomes.<h4>Methods</h4>We performed a two-center, retrospective observational cohort study of patients with IMDC who received SITs following steroids from 2016 to 2020. Patients' demographic, clinical, and overall survival data were collected and analyzed.<h4>Results</h4>A total of 184 patients (62 vedolizumab, 94 infliximab, 28 combined sequentially) were included. The efficacy of achieving clinical remission of IMDC was similar (89% vs 88%, p=0.79) between the two groups.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-06-10T05:48:36.801Z","creation":"2022-02-11T13:34:21.408Z"},"accession":"S-EPMC8601082","cross_references":{"pubmed":["34789551"],"doi":["10.1136/jitc-2021-003277"]}}